later, in 1970, his attending physician prescribed thioridazine to control "aggressive and sexual behaviours" which were not directly observed by the physician. A consulting psychiatrist recommended treatment with small doses of thioridazine as well as close observation of the patient. However, the attending physician increased the dose of thioridazine and added other neuroleptics to Clite's treatment.
In 1974, abnormal movements of the face and tongue appeared and were diagnosed as symptoms of TD. Despite the diagnosis, the neuroleptic treatment was not changed and the patient's condition continued to deteriorate. This deterioration was later regarded by the court as stemming from the neuroleptic treatment. The parents of the patient asked that the neuroleptic medication be discontinued, but this request was denied.
In 1977 a lawsuit was launched against the hospital and the state of Iowa by the patient's father. In 1980 the court awarded $760,000 to the plaintiff. The main considerations in the ruling were the inadequate monitoring of the patient before the appearance of the dyskinetic syndrome (Clite's records indicated that he had not been physically examined or regularly visited by a physician for three consecutive years) and the failure of the hospital staff to react to the developing signs of TD. The Appellate Court upheld the ruling and included in it the lack of informed consent from the patient's family. The court viewed the use of medication as a kind of chemical straight jacket used to control the patient's behaviour, primarily for the convenience of the staff.
The issue of diagnosis is important in this case since the patient did not suffer from a psychotic disorder but was mentally retarded. In 1979 the APA Task Force Report on Tardive Dyskinesia stated that long term neuroleptic drug therapy is indicated for schizophrenia, paranoia, childhood psychoses, and certain neuropsychiatric disorders such as Gilles de la Tourette's syndrome and Huntington's disease (2) . The task force report also stated that the use of antipsychotics for conditions treatable with other agents such as anxiety, non delusional depression and insomnia, should be avoided as much as possible (2) . Nevertheless, with clinical and economic pressures the use of neuroleptics to control agitation and aggressive behaviours in mentally retarded institutionalized patients is not uncommon. What is important to consider is the use of minimal effective doses of neuroleptics used for the shortest possible time, and other pharmacological strategies such as benzodiazepines, carbamazepine, and even lithium (20) . This case clearly illustrates the importance of thoroughly documenting the reasons which motivate neuroleptic use, and the patient's response to treatment. It also emphasizes the need for close monitoring of patients on maintenance neuroleptic drug therapy.
Faigenbaum vs. Cohen
Anita Faigenbaum-Katz was hospitalized in 1964 and again in 1966 for manic episodes which responded well to moderate doses of chlorpromazine. She remained asymptomatic and functioned well, until 1976 when she suffered a manic relapse that required hospitalization in a state psychiatric hospital (following the breakdown of her marriage). Between March and November 1976 she received 400 doses of chlorpromazine, varying from 25 to 100 mg each.
In October of the same year, the patient started presenting abnormal movements which her psychiatrist attributed to her mental state. Throughout 1977 the patient was hospitalized and received chlorpromazine, trifluoperazine, haloperidol, and perphenazine and amitriptyline combined (triavil). Several diagnoses including a bipolar disorder were considered, and during this period her abnormal movements worsened. After seeing the patient in consultation three times, a neurologist concluded that the patient was suffering from Huntington's chorea (although there was no family history of it and without a cerebral CAT scan) and recommended that treatment with haloperidol be continued. The diagnosis of tardive dyskinesia was considered twice by junior consultants but was not accepted by the attending psychiatrist nor by the consulting neurologist. In 1977 the family successfully stopped the neuroleptic treatment. In 1978 a second consulting neurologist described the abnormal movements of the patient as "one of the worst cases of tardive dyskinesia I have ever seen. " During this period, the involuntary movements persisted and the mental state of the patient declined. According to expert psychiatric testimony, a tardive psychosis was considered as a possible explanation for the patient's deteriorating mental state.
In 1979 a lawsuit against the state of Michigan, 11 doctors, two hospitals and three pharmaceutical companies was initiated. In the ruling which granted $1,000,000 (plus legal costs and interest) to the plaintiff, the court's concerns were that the neuroleptic treatment was not properly implemented, the diagnosis of TD was missed by the treating psychiatrist and a consulting neurologist, and that the neuroleptic medication was continued despite the clinical picture of abnormal move-. ments and despite objections raised by the family and patient.
This case raises the issue of treating bipolar disorder patients with long term neuroleptic medication. Acutely manic patients are commonly treated with both lithium and antipsychotics. It is possible to decrease the use of antipsychotics in these patients by using benzodiazepines in combination with lithium, which has been shown to be an effective treatment strategy in acute mania (21) (22) (23) (24) (25) . However, there is potential for chronic benzodiazepine use in this population and particular attention must be given to decreasing and withdrawing benzodiazepines as early as possible. While maintaining bipolar patients on chronic neuroleptic drug therapy is not generally recommended, for a few severely affected patients whose compliance or clinical response to lithium and other agents is poor, such a treatment alternative can be helpful in controlling the underlying psychopathology. In such patients carefully documenting the reasons for maintenance neuroleptic treatment is essential since affective disorder patients may be at increased risk of developing tardive dyskinesia (1, (3) (4) (5) 26, 27) .
Hedin vs United States
In 1975, Larry Hedin was admitted to a Veterans Administration (VA) hospital in Dallas, Texas for amphetamine and alcohol dependence. A year later he was admitted to a VA hospital in Minnesota for his alcohol abuse and was treated with diazepam and thioridazine. Five months later, this treatment was replaced with chlorpromazine which continued for 46 months at doses varying from 400 to 600 mg daily.
In 1980 a physician diagnosed tardive dyskinesia and discontinued the patient's chlorpromazine. According to testimony, the dyskinetic syndrome led to the breakup of Hedin's marriage and the loss of his job. The patient sued the Veteran's Administration, requesting ten million dollars in damages. As an outpatient of the VA hospital, he had not seen a physician for 17 months during which time the hospital continued to fill his neuroleptic prescriptions through the mail. The defense did not object to the allegations of the plaintiff and recognized that medication was not appropriately managed. In 1984 the court awarded him more than $3,000,000 in damages, legal costs and interest and ruled that the neuroleptic dose was excessive and that there was a lack of adequate treatment supervision.
This case is of particular relevance to the long term followup of schizophrenic outpatients on maintenance neuroleptic drug therapy. Stable outpatients who are employed in the community or others with a valid reason may request renewal of their medication for a period of several months without actually seeing a physician. This situation can pose a dilemma for the clinician who must consider (ideal) professional standards of practice on one hand and the reality of heavy followup caseloads on the other. There are no clearly established guidelines in such circumstances and the clinician should use his own judgement. However, clinicians who regularly prescribe maintenance neuroleptic drug therapy by mail, telephone, or by other means without personally examining the patient for several months should review this standard of practice .
Headley vs Hannekan
Beginning in 1968 Lela Headley was treated in a state psychiatric hospital with thiothixene. Two years later she developed a spasmodic torticollis which resembled a dyskinetic syndrome. Her neuroleptic treatment was not changed. In 1981 she developed abnormal bucco-lingual movements which were diagnosed as tardive dyskinesia by a second doctor, who discontinued the neuroleptic treatment. The patient filed a suit against the first physician for not having informed her of the early symptoms of TD. The argument put forward by the first physician was that there was the possibility of inducing TD symptoms by "suggestion" had he warned the patient. This argument did not stand up in court and the plaintiff was awarded $315,000 in damages and interest.
Barclay vs Campbell
This lawsuit raises the issue of informed consent with regard to neuroleptic treatment and risks of tardive dyskinesia. Barclay was a young male schizophrenic treated with neuroleptics without being informed of their possible risks. He developed TD quite early in his treatment and sued his physician for negligence and not providing information about the risks of TD. The case was dismissed by the Texas Appellate Court, which ruled that the risks of TD were minimal in the patient given his age, the length of neuroleptic treatment, and the dosage used.
The court stated that Barclay did not meet the' 'reasonable person standard" and that if he had been informed of the possible risks, he probably would not have accepted treatment. The "reasonable person standard" and the "Canterbury standard" are "need to know" standards based on the information a reasonable person requires to give informed consent (9, to, 18, 19, 28) . Adequate information constitutes only one of three elements of the informed consent process. The other two elements are voluntariness of the patient in absence of coercion (for example, by family, physicians, the institution) which would impede his or her autonomy and competency, which requires that a patient possess sufficient mental ability to participate meaningfully in the decision making (19) .
In 1983, informed consent regarding neuroleptic treatment was the object of a cautionary recommendation made by the Secretary General of the Corporation of Physicians of Quebec, which stated: "the patient has to be informed (about the advantages or inconveniences of treatment) and the most serious adverse consequences which may occur should be explained" (29).
Physicians may be reluctant to discuss the risks of neuroleptic use with their patients. The truth is, it is not easy to tell a patient that the medication he benefits from may also lead to the emergence of tardive dyskinesia. It is only with practice and experience in adapting various approaches to each patient that a physician can truly become comfortable with this process. Resistance to discussing TD can also stem from the institution as well as the patients themselves (31) . However, it is our experience that most patients react to the information with less anxiety than the physician! Recent studies, which compare patients who are not informed with those who are, have shown that when patients are given information about the possible long term effects of neuroleptic therapy, there is no increase in non compliance to their treatment as opposed to compliance (31) (32) (33) (34) .
In one study, patients who received an informal oral presentation on tardive dyskinesia retained significantly more information over a two month period than patients who received a formal written presentation (31) . However, neither group retained the information considered by the authors to be most important in deciding on neuroleptic drug therapy. It is important that these discussions between the physician; the patient and his family be summarized and documented on the chart (I ,31). It would be premature to discard the value of the written consent form, which in a recent study was shown to be clearly beneficial to patients (32) . Written consent forms do not offer complete protection against a claim of lack of informed consent, and regardless of whether or not consent forms are used, patient progress notes should indicate that the discussion of risks, benefits, and alternatives to neuroleptic therapy is a continual process (19) .
A question often asked is how soon after the initiation of antipsychotic drug treatment should informed consent be obtained. Some acutely psychotic patients do not have the capacity to give true informed consent. It is a wise approach to delay the consent procedure until the condition of the patient has remitted enough to allow reasonable participation. This delay can last anywhere from a few weeks to six months and can be justified since the risk of developing TD during this period is low (1, 19) . .
The case of Barclay vs Campbell opens the way for other challenges based on informed consent. The ruling might have been different had the patient been an elderly female, for whom the risk of developing TD is greater (1, 3, 35) .
Conclusion
In four of the five cases reviewed, the court found in favour of plaintiffs, who were awarded sums varying from $315,000 to $3,000,000 US. These five lawsuits were all filed in the United States and the publicity surrounding them has made the public aware of their rights regarding patient education to side-effects of medications and the possible "price" of tardive dyskinesia in litigation cases. It is important to mention however that most of the cases reviewed involved gross negligence on the part of the treating physicians. Careless psychiatric practice can not only lead to large awards but may also encourage further TD litigation. The principal motives for such litigation are: 1. inappropriate use of neuroleptics; 2. 'lack of periodic reevaluation of treatment; 3. undiagnosed TD; 4. lack of informed consent; and 5. lack of patient information upon early detection (1, 9) .
The current situation in Canada is certainly not comparable to the one in the United States, and to our knowledge tardive dyskinesia litigation cases have yet to appear before Canadian courts. While we are not immune to the possibility of eventual lawsuits related to the disorder, it is important that we continue to recognize the efficacy of neuroleptic drugs, which have revolutionized the treatment of schizophrenia.
Because of a lack of effective treatment, it is essential to prevent TD. Primary prevention includes limiting the use of long term neuroleptic drug therapy to primarily schizophrenia. Prior to the initiation of neuroleptic drugs, patients should be examined to determine the presence of any pre-existing movement disorders and reexamined at periodic intervals. It is particularly important for physicians to be aware of the subgroup of patients who are at increased risk for the disorder. Advancing age is the most predisposing risk factor for TD (1) (2) (3) (4) (5) (6) (7) (35) (36) (37) ; being female is thought to be the second most predisposing risk factor (1) (2) (3) (35) (36) (37) . Several reports note that affective disorders may be a risk factor for TD, yet it is not clear if schizophrenia is a risk factor or a protective factor for the disorder (l, [3] [4] [5] 26, 27) . Recent data strongly suggest that vulnerability to parkinsonism constitutes a significant risk factor for TD (35, 38, 39) . Furthermore, recent evidence suggests that the cumulative incidence of TD increases with duration of neuroleptic exposure, and that at least during the first four to five years of neuroleptic treatment, the increase is relatively linear (38) (39) (40) .
Secondary prevention consists of limiting the duration of neuroleptic treatment, especially among first break episode patients, and using the lowest possible dose for maintenance treatment (l, 9, 35, 41) . Clinical rating scales such as the Abnormal Involuntary Movement Scale (AIMS) (42) or the Extrapyramidal Symptom Rating Scale (ESRS) (43) used every six months may detect early signs ofTD. Early detection may help slow or reverse its progression. Although new avenues in therapeutic research are emerging (l ,44-50), the present treatment of choice for tardive dyskinesia is the gradual reduction of antipsychotic drug treatment when possible (1) . Discontinuing drug treatment generally stabilizes or reduces TD symptoms for the majority of chronic schizophrenic patients. Maintenance neuroleptic drug therapy at low to moderate doses (300 to 600 mg/day of chlorpromazine equivalents, or less) is frequently associated with a course of stabilizing or reducing TD symptoms (l ,37). Knowledge of the syndrome in its diverse heterogenous clinical manifestations, differential diagnosis and epidemiology, particularly regarding risk factors is necessary for the recognition and diagnosis of the syndrome (l, [51] [52] [53] . Regular assessments of the neuroleptic treatment, use of minimal effective doses, periodic renewal of informed consent, examining patients at regular intervals to detect early signs of TD, and documenting these steps, is invaluable in assessing the benefit to risk ratio of neuroleptic therapy in each patient (I). It is hoped that the development of new antipsychotic drugs with lesser potential to induce extrapyramidal syndromes might lead to a significant decrease in TD in the near future (54) (55) (56) .
